Vicept Therapeutics gets funding for V-101

News across the business web sites today a new company obtaining funding for a patent protected alpha-adrenergic receptor based treatment for the redness of rosacea.

Vicept Therapuetics is based in Malvern in Pennsylvania and is a privately held company.

From Fidelity Biosciences Joins $10M Series A for Vicept Therapeutics

“We are delighted by the strong investor interest in this round of financing which will allow us to continue to advance the development of our product pipeline utilizing our novel, patent protected α-adrenergic receptor technology for the treatment of diseases of the skin,” added Dr. Walker. “With this investment, we will have the necessary resources to continue progress with our lead candidate through Phase II for rosacea as well as pursuing other dermatologic conditions including actinic purpura and peri-procedural bruising of the skin.”

Great to see another company getting funding to develop new treatments for rosacea. Obviously there is a belief by venture capitalists that rosacea is a growth market, especially for the treatment for erythema.

The following patent looks likely to be related to the company and their product development.

COMPOSITIONS AND METHODS FOR TREATING PURPURA

(WO/2009/065116)

PCT/US2008/083774

VICEPT THERAPEUTICS, INC

SHANLER, Stuart D; ONDO, Andrew

Embodiments of the present invention are directed to compositions and methods for the treatment of purpura. Preferred compositions comprise an α adrenergic receptor agonist selected from selective α1 adrenergic receptor agonist, selective α2 adrenergic receptor agonist, non-selective α12adrenergic receptor agonist, agents with α2 adrenergic receptor agonist activity and combinations thereof, in a pharmaceutically acceptable carrier in order to treat and improve the cosmetic appearance of hemorrhagic (purpuric) lesions in the skin.

The authors of this 2009 patent describe some trials where the following formulations were trialled;

  • Oxymetazoline hydrochloride from Afrin Original 12 Hour Nasal Spray
  • Naphazoline hydrochloride from Clear Eyes Maximum Redness Relief
  • Tetrahydrozoline hydrochloride from Visine Original
  • Phenylephrine hydrochloride from Neo-Synephrine Extra Strength Spray
  • Brimonidine tartrate from Bausch & Lomb
  • Oxymetazoline hydrochloride and brimonidine tartrate combined.

The results of this trial claimed;

… that this demonstrates that selective αi adrenergic receptor agonists and selective α2 adrenergic receptor agonists, used separately or in combination, when topically applied to and around a treatment site after a procedure that can/will induce purpura, will reduce the size and appearance of the purpuric macules/ patches and is an effective treatment to hasten their resolution.

The source of the purpura in this instance was a pulse dye laser at 585nm.

The publishers of this patent have an additional similar patent that was mentioned by Rosacea News  in 2007;  Sansrosa’s sister to enter redness race

Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using a1-adrenoceptor agonists

United States Patent Application 20050165079

Shanler, Stuart D.(New York, NY) ; Ondo, Andrew(Las Cruces, NM)

The present invention is directed to the treatment of skin erythema as exhibited in rosacea and other conditions characterized by increased erythema (redness) of the skin. These conditions exhibit dilation of blood vessels due to a cutaneous vascular hyper-reactivity. In particular, the present invention is directed to a novel composition and method for the treatment of skin erythema using .alpha..sub.1-adrenergic receptor (.alpha..sub.1-adrenoceptor) agonists incorporated into cosmetic, pharmacological or dermatological compositions for topical application to the skin.

Whilst it appears that no new molecules have been discovered, these patents, if allowed, will protect the usage of these formulations to treat the redness of several skin conditions including rosacea. As we have seen with the Sanrosa product it can take many years and a large investment in R&D to progress from a discovery to a sellable product. It is great news that Vicept has secured funding to begin this drug approval process.

[update]:From a press release dated January 10, 2011, Vicept Therapeutics Announces Positive Phase 2 Data of V-101 for the Treatment of Type I Rosacea (Erythematotelangiectatic Rosacea)

Vicept Therapeutics, Inc. announced today positive study results from a Phase 2 clinical trial evaluating the dose-response relationship of 4 concentrations of V-101 cream, a topical cream for the treatment of Type I Rosacea (Erythematotelangiectatic Rosacea). The results demonstrated a highly statistically significant (p=0.006) improvement in the primary end point, which was a reduction in facial erythema, over an eight hour period in patients with erythematotelangiectatic rosacea (ETR), versus placebo. Further, V-101 demonstrated a safety profile similar to placebo cream and no evidence of “rebound” or tachyphylaxis was observed.

“These positive data showed that V-101 significantly reduced the redness associated with Type I rosacea (ETR) and demonstrated a favorable side effect profile, further confirming its potential to be the first effective topically applied therapy directed specifically toward the erythema of rosacea,” said Dr. Neal Walker, President and Chief Executive Officer of Vicept. “This is a major milestone for the Company and we intend to continue to advance the V-101 development program.”

Study V-101-ROSE-202 is a prospectively randomized, multi-centered, double-blinded, placebo-controlled, Phase II clinical trial designed to evaluate the dose-response relationship of four concentrations of V-101 cream vs. vehicle (placebo) for the treatment of the erythema associated with rosacea. A total of 183 patients with moderate to severe erythema participated at seven investigational centers across the United States. Patients were divided among five groups and self-administered one of four concentrations of V-101 cream or vehicle (placebo) cream once daily for 28 days. The study also demonstrated that V-101 cream was extremely well-tolerated in these patients with ETR, a population of patients with facial skin that is highly sensitive to topical preparations. The safety profile of all the active preparations was similar to that of placebo.

Related Articles

About the Author

About the Author: David Pascoe started the Rosacea Support Group in October 1998. .

Follow Rosacea Support

Subscribe via RSS Feed Connect on Pinterest Connect on Google Plus

1 Reader Comment

  1. Dukecity says:

    In phase2 clinical trials now.

Leave your comment here

Top

Subscribe to Rosacea News

Enter your email address to receive the latest news about rosacea in your inbox.